Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man

Sanja Dragovic1 · Nico P. E. Vermeulen1 · Helga H. Gerets2 · Philip G. Hewitt3 · Magnus Ingelman-Sundberg4 · B. Kevin Park5 · Satu Juhila6 · Jan Snoeys7 · Richard J. Weaver8

Received: 14 August 2016 / Accepted: 29 August 2016 / Published online: 22 September 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract The current test systems employed by pharmaceutical industry are poorly predictive for drug-induced liver injury (DILI). The ‘MIP-DILI’ project addresses this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test systems, bioanalysis and systems analysis is adopted to evaluate existing models and develop new models that can provide validated test systems with respect to the prediction of specific forms of DILI and further elucidation of mechanisms. An essential component of this effort is the choice of compound training set that will be used to inform refinement and/or development of new model systems that allow prediction based on knowledge of mechanisms, in a tiered fashion. In this review, we focus on the selection of MIP-DILI training compounds for mechanism-based evaluation of non-clinical prediction of DILI. The selected compounds address both hepatocellular and cholestatic DILI patterns in man, covering a broad range of pharmacologies and chemistries, and taking into account available data on potential DILI mechanisms (e.g. mitochondrial injury, reactive metabolites, biliary transport inhibition, and immune responses). Known mechanisms by which these compounds are believed to cause liver injury have been described, where many if not all drugs in this review appear to exhibit multiple toxicological mechanisms. Thus, the training compounds selection offered a valuable tool to profile DILI mechanisms and to interrogate existing and novel in vitro systems for the prediction of human DILI.

Keywords Drug-induced liver injury (DILI) · MIP-DILI · Set of training compounds · Evidence-based selection · DILI mechanisms

Introduction

The appropriate selection of compounds for use in the evaluation of existing and novel model systems for the improved, and mechanism-based prediction of DILI in man requires special attention to overarching goals and strategies of the research programme. It is important to evaluate evidence for mechanisms that actually occur in patients. In the case of the MIP-DILI consortium (www.mip-dili.eu),
the strategy of compound selection was to adopt a two-tiered approach towards compound selection. The first tier was to adopt an evidence-based evaluation of drugs with perceptively known mechanism of toxicity and propensity to cause liver toxicity in the human population. The first tier of compounds, defined as *training compounds*, would serve to probe existing and novel in vitro and in vivo model systems for use in defining a panel of improved assays for use in pharmaceutical research and development. The second tier, defined as *test compounds*, by contrast, comprises of legacy compounds from EFPIA Pharmaceutical companies previously known to cause liver injury in man or other (toxicology) species, but for which the mechanism(s) are poorly described. This paper describes the selection and compilation of known human DILI mechanisms on the set of training compounds identified for use in MIP-DILI.

For the evidence-based training compounds, the MIP-DILI consortium aimed to use new knowledge gained during the project to further challenge existing and novel in vitro and in vivo systems for their value in both the understanding and prediction of DILI in man through complementary experimental and computational modelling paradigms to generate quantitative outputs for use in predictive drug liver injury through use of a tiered and iterative strategy (Fig. 1).

**Definition of training and test compounds**

To support the concept of training and test compounds for use in the MIP-DILI consortium, definitions of each of these sets of compounds have been defined, as a consensus agreement, by which to select compounds for use in the evaluation model systems.

*Training compounds* were defined as suitable ‘Drugs associated with biological processes which are presently thought to be relevant to the initiation or prevention of DILI in man, alongside an appropriate negative control’.

*Test compounds* (EFPIA legacy compounds): ‘Drugs which are associated with DILI in either preclinical or clinical studies and could be potentially developed into a MIP-DILI training compound’.

**Mechanisms of drug-induced liver injury**

The mechanisms by which most drugs cause liver injury are still poorly understood and subsequently hinder the detection of the hepatotoxic potential of drugs during preclinical and early clinical development. For the most part, mechanisms are based on studies in single in vitro or animal model test systems without any direct read across to the clinical situation. An essential step in the selection and use of training compounds and test systems is a consideration of their pharmacological and physiological relevance to man.

Many drugs are lipophilic substances and require transformation into metabolites by the phase I enzymes with subsequent conjugation by phase II enzymes to form water-soluble metabolites. While the majority of metabolites form readily excreted bio-inactive metabolites, phase I and to a lesser extent phase II enzymes also can metabolize drugs to electrophilic chemically reactive metabolites (CRMs) or unstable, reactive conjugates with the propensity to covalently bind macromolecular molecules in cells; the long-term persistent formation of which are believed to cause cellular dysfunction and liver injury (Srivastava et al. 2010). Furthermore, it is now clear that the intracellular concentration and persistence of a number of drugs is highly dependent on transporters which show variable expression. Knowledge of the disposition of training and test compounds in man is therefore vital for the interpretation of data from model systems. Coupled with the metabolic capacity of the liver, pre-existing liver disease, age, genetic variation, oxygen supply and the intrinsic properties of drugs, all are considered to predispose the liver to cellular injury and death.
Recent advances in our understanding of cell death modalities, based on biochemical and cellular insights, reveal a host of subtle yet distinct pathways defining programmed cell death through apoptosis and necrosis pathways, as opposed to the classical view of regulated and non-regulated cell death (Vandenabeele et al. 2010; Papatriantafyllou 2012). Recent research suggests necrosis, in part, is mediated through programmed cell death (necroptosis) through activation by tumour necrosis factor alpha (TNFα), Fas ligand (FasL) and tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) by ligands also implicated in apoptosis (Degterev et al. 2005). Necrotic cell death follows antioxidant consumption and oxidation of cellular macromolecular proteins, in turn potentially affecting mitochondrial membrane permeability, loss of mitochondrial membrane potential, decrease in ATP synthesis and disruption of Ca2+ homeostasis. The mechanism of necroptosis is believed to be mediated through reactive oxygen species (ROS) production in response to TNFα activation (Lin et al. 2004).

In contrast to necroptosis, programmed cell death also occurs through the more widely established activation of a family of cysteine proteases and caspases, to mediate apoptotic cell death. Activation of caspases therefore occurs in response to agonistic death ligands, TNFα, FasL and TRAIL, and/or mitochondrial damage through the activation of pro-apoptotic BH-3 members of the Bcl-2 family of ligands (Degterev et al. 2005; Christofferson and Yuan 2010). While drug-mediated necrotic events are emerging for hepatotoxic drugs (Han et al. 2007; Dunai et al. 2012), it is widely accepted that many drugs cause liver injury through the caspase-dependent apoptotic pathways of cell death.

Apoptotic-inducing drugs are believed to alter the energetic state of mitochondria thereby placing the role of mitochondria as central to drug-mediated apoptotic hepatocellular injury and death. However, the previous classification of apoptotic and necrotic pathways is perhaps now less clear for drug-related cell death, where roles for adenine nucleotide translocase and cyclophilin are implicated in membrane transition pore opening—a mechanism well recognized among several hepatotoxic drugs (Masubuchi et al. 2002, 2005).

Non-parenchymal cells may also be targets in DILI with the activation of the immune system and subsequent idiosyncratic reactions in which human leucocyte antigen (HLA) genotypes are implicated in the aetiology of these types of liver injury. Consideration of these mechanisms of DILI forms the basis for the selection of a training set of compounds based on clinical pathology of liver injury, but where the actual mechanism of DILI remains to be better defined. Therefore, present day knowledge of mechanisms of liver injury forms the basis for selection of training compounds that are relevant to liver injury at the cellular level. While drugs are central to the mechanism-based selection of training compounds involved in liver injury, non-drugs such as rotenone may be valuable as reagents for use in demonstrating the relevance of in vitro models for the prediction of DILI in man, particularly with respect to understanding specific molecular initiating events and molecular pathways leading to DILI. It must be noted that DILI can be a multi-step and multicellular event and therefore drugs may be ‘complex reagents’.

In addition to the selection of compounds with known mechanisms affecting mitochondrial function, are those known to cause liver toxicities as a consequence of changes in the physiological function of the bile acid transport network and steatosis. Among the many transporter proteins regulating the uptake and efflux of drugs and metabolites is the transport protein bile salt export pump (BSEP), the inhibition of which is implicated in the aetiology of several drug-induced liver toxicities.

The overarching goal of training compound selection is to develop a panel of best practice in vitro assays. However, the limitation of a mechanism-based strategy for the selection of training set of compounds relies on our present understanding of the mechanisms. The challenge, therefore, is to select training compounds based on our present mechanistic knowledge of cellular liver injury, yet contribute to our understanding and evaluation of existing and novel model systems for both the understanding and the prediction of liver injury in man.

**Acute and chronic forms of liver injury**

The rationale of chronic versus acute dosing is to delineate if acute dosing and repeated dosing leads to the same mechanism of toxicity (Ramachandran and Kakar 2009). For example, acute toxicity of CCl4 leads to centrilobular necrosis, but on cessation the liver fully recovers. By contrast, long-term exposure or repeated exposure leads to a centrilobular adaptation and finally to peripheral fibrosis. Overdose of APAP by contrast leads to necrosis with either fulminant liver failure or recovery and no fibrosis even following long-term repeated administration. Nitrofurantoin is another example that, on the one hand, can cause rare reversible acute liver injury and, on the other hand, more common chronic hepatitis with autoimmune-like features.

These examples of liver toxicants illustrate the a priori requirement to select training compounds on the basis of an understanding of the mechanism(s) of liver injury, such that these mechanisms are recapitulated in in vitro cellular-based assays. Nevertheless, in the selection of training compounds, the challenge is to understand these mechanisms as they relate to in vivo liver injury in human in both acute and chronic drug administration in patient populations.
Training compound selection was made by representatives from both EFPIA companies and academia in the MIP-DILI consortium using data compiled by partners and assembled for evaluation in a purposely built Central data repository (CDR) for the compilation of background and foreground data. The goal was to select 10 training compounds positive for their propensity to cause DILI in man and, where possible, chemically matched negative compounds.

Criteria for the selection of training compounds are summarized in Table 1. The selection of training compounds was identified to broadly cover liver toxicity as defined by the perceived or known mechanisms of chemical insult and hepatocellular injury. The mechanisms of hepatocellular injury are broadly classified into five main areas namely (1) mitochondrial dysfunction, (2) chemically reactive metabolites and necrotic toxicity, (3) lysosomal dysfunction, phospholipidosis and steatosis, and (4) bile transport inhibition for the study of mechanisms of cellular injury in in vitro cellular-based models, and to include (5) adaptive or immune-mediated mechanisms believed to involve, but not restricted to, HLA phenotypes (Fig. 2).

Compound selection focused on marketed or formally marketed drugs known to exhibit DILI in man, including both dose-dependent and idiosyncratic dose-dependent toxicities. Of the 40 compounds nominated, 10 compounds were selected as training compounds for use in the initial phase of the research programme (Table 2). Acetaminophen (APAP), amiodarone, diclofenac, fialuridine, and tolcapone were selected on evidence of mitochondrial dysfunction; APAP, diclofenac, nefazodone, tolcapone, and troglitazone on the formation of reactive metabolites; amiodarone, perhexiline, and troglitazone on causing lysosomal impairment and bosentan, diclofenac, nefazodone, perhexilene, and troglitazone as inhibitors of transport proteins (Table 2). Ximelagatran and flucloxacillin were selected among a number of immune-mediated liver toxicities. Where possible, matched negative controls were identified, which in the case of tolcapone and troglitazone were entacapone and pioglitazone, respectively. Chemical structures of MIP-DILI training compounds and negative controls are shown in Table 3.

### Idiosyncratic toxicity and toxicity profiles of selected training compounds

#### Idiosyncratic toxicity

Drug-induced liver injury can be predictable and unpredictable (‘idiosyncratic’). Predictable liver toxicity is dose-dependent and, essentially, all patients will develop...
liver injury if they receive a sufficiently high dose of the hepatotoxic drug. The toxicity of APAP remains one of the most extensively studied drugs known to cause dose-dependent liver toxicity in humans and preclinical species (Larson 2007). The term idiosyncratic means that the occurrence of DILI is a function of the individual. Such reactions may have an immunological basis, but this must not be assumed.

Alternatively, drugs known to form chemically reactive metabolites (CRMs) can be associated with idiosyncratic toxicity. These drugs which form CRMs provide evidence of a possible link between reactive metabolite formation and idiosyncratic liver toxicity—not necessarily dose-dependent, occurring only in a small fraction of susceptible individuals and within the intended therapeutic range (Uetrecht 2000). Idiosyncratic adverse drug reactions (IDRs) associated with liver injury are reported in 50 % of the cases of acute liver failure (Abboud and Kaplowitz 2007), but the frequency of IDRs is low accounting for 1 in 10,000—1 in 100,000 patients. IDRs are often not identified until the drug reaches a large patient population. In Table 4, an overview is given of the selected training compounds involving the relevant processes and mechanisms in DILI.

Below the relevant mechanisms for DILI of the training compounds will be illustrated using representative training compounds. For details on the relevant processes and mechanisms involved in DILI of all training compound, reference is made to Table 5.
Table 3  Chemical structures of MIP-DILI training compounds

| Acetaminophen | Amiodarone | Bosentan |
|---------------|------------|----------|
| ![Acetaminophen Structure](image1) | ![Amiodarone Structure](image2) | ![Bosentan Structure](image3) |

| Diclofenac | Fialuridine | Nefazodone |
|------------|-------------|------------|
| ![Diclofenac Structure](image4) | ![Fialuridine Structure](image5) | ![Nefazodone Structure](image6) |

| Perhexiline | Tolcapone | Troglitazone |
|-------------|-----------|--------------|
| ![Perhexiline Structure](image7) | ![Tolcapone Structure](image8) | ![Troglitazone Structure](image9) |

| Ximelagatran | Flucloxacillin | Buspirone (negative compound) |
|--------------|----------------|------------------------------|
| ![Ximelagatran Structure](image10) | ![Flucloxacillin Structure](image11) | ![Buspirone Structure](image12) |

| Entacapone (negative compound) | Metformin (negative compound) | Pioglitazone (negative compound) |
|-------------------------------|------------------------------|---------------------------------|
| ![Entacapone Structure](image13) | ![Metformin Structure](image14) | ![Pioglitazone Structure](image15) |
Compounds causing mitochondrial impairment (mechanism 1)

Mitochondrial dysfunction is a general term to include alterations of different metabolic pathways and damage to mitochondrial components (Fig. 3.1). Changes in mitochondrial homoeostasis can have a variety of deleterious consequences, such as oxidative stress, energy depletion, accumulation of triglycerides, and cell death. Mechanisms of mitochondrial dysfunction include membrane permeabilization, oxidative phosphorylation (OXPHOS) impairment, fatty acid β-oxidation (FAO) inhibition and mtDNA depletion. Regarding steatosis, investigations suggest that besides mitochondrial dysfunction several other mechanisms could be involved and they are discussed separately below using the training compounds as umbrella.

Fialuridine (mechanism 1)

Fialuridine was developed as an antiviral therapy for hepatitis B infection. In a phase II study, fialuridine caused severe toxicity: irreversible acute hepatic failure in 7 out of 15 patients, myopathy, myoglobinuria, severe lactic acidosis, and neuropathy after 9–13 weeks of treatment (McKenzie et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995). Five out of 7 participants with severe hepatotoxicity died and two survived after liver transplantation (McKenzie et al. 1995). Preclinical toxicology studies in mice, rats, dogs, and primates did not provide any indication that FIAU would be hepatotoxic in humans (Trials et al. 1995).

Histologic analysis of human liver tissue showed prominent accumulation of microvesicular fat, with chronic active hepatitis and variable degrees of macrovesicular steatosis, but little hepatocellular necrosis, which is consistent with the absence of substantial elevations in serum aminotransferase levels during treatment. Electron microscopy showed markedly swollen mitochondria, with loss of cristae, matrix dissolution, and scattered vesicular inclusions.

In studies of fialuridine in a human hepatoma cell line (Hep G2), the drug was incorporated into both nuclear and mitochondrial DNA, but at a much higher rate in the latter (Cui et al. 1995). Morphologic changes in mitochondria, microsteatosis, macrosteatosis, and increased lactic acid production were also observed. The integration of nucleoside analogues into nuclear DNA represents an alternative but potentially delayed pathway to cytotoxicity and cell apoptosis. Expression of a nucleoside transporter hENT1 in human (but not in mouse) mitochondria, which facilitates entry of fialuridine into mitochondria, may be responsible for the human-specific mitochondrial toxicity caused by fialuridine (Lee et al. 2006).

Recently, it has been shown that chimeric mice could be used as a model for fialuridine toxicity. The clinical features, laboratory abnormalities, liver histology, and ultrastructural changes observed were the same as in humans and these abnormalities developed in the regions of the livers that contained human hepatocytes but not in regions that contained mouse hepatocytes (Xu et al. 2014).

Reactive metabolites (mechanism 2)

Involvement of the liver in drug-related injury rests on the anatomical location of the liver and exposure to orally ingested drugs, physiology and metabolic capacity of the drug-metabolising enzymes. During drug absorption, some of the parent drug is metabolized to typically more hydrophilic entities, the metabolites of which are predominantly inert water-soluble metabolites, but can equally lead to the formation of chemically reactive species, i.e. reactive metabolites (Fig. 3.2). And the process of drug bioactivation to CRMs is believed to be among the number of initiating events of many drug-related liver toxicities. The formation of CRMs can interact with...
Table 5  Details of relevant processes and mechanism involved in DILI of the training compounds

| Training compound | Phase I | Phase II | Phase III and BSEP inhibition | Cell death | Mitochondrial dysfunction | Lysosomal dysfunction and phospholipidosis | Immune response | Association studies |
|-------------------|---------|----------|-------------------------------|------------|--------------------------|------------------------------------------|----------------|---------------------|
| Acetaminophen     | Mainly glucuronidation and sulfation | Unlike APAP, elimination of APAP metabolites require transporters | Majority of animal studies suggest necrosis | Associated with binding of NAPQI to mitochondrial proteins |
|                   | NAPQI, CRM responsible for APAP-hepatotoxicity | Biliary excretion: APAP-glucuronide—MRP2 and BCRP; APAP-sulphate: MR2 and BCRP; APAP-GSH: MRP2 | Increasing number of reports suggest apoptosis also plays a key role |
|                   | CYP2E1 is primary enzyme, other CYPs (including CYP1A2 and CYP3A4) also involved in bioactivation | Basolateral excretion: APAP-glucuronide: MRP3, APAP-sulphate: MRP3 and MRP4 |
|                   | At therapeutic dose NAPQI is efficiently deactivated through spontaneous or enzymatic (GST) GSH conjugation | |
|                   | Overdose of APAP results in GSH depletion and protein binding | |
| Amiodarone        | Glucuronide conjugation is an important elimination pathway of amiodarone and its phase 1 metabolites (conjugates found in human bile) | Amiodarone and DEA are excreted through the biliary system | Micro- and macrovesicular steatosis, phospholipid laden lysosomes (phospholipidosis, impairment of lysosomal function), intense ballooning of hepatocytes, presence of abundant mallory bodies, and fibrosis | Inhibition of mitochondrial beta-oxidation → triglyceride accumulation and macrovesicular steatosis |
|                   | Primarily metabolized to its active metabolite, mono-N-desethylamiodarone (DEA) by several hepatic CYPs (primarily by CYP3A4 but also CYP1A1, 2D6 and 2C8) | Inhibitory effects of amiodarone towards Phase 3 transporters observed (primarily uptake, OATP2) | Pseudoalcoholic hepatitis | Accumulation in lysosomes and trapping due to protonation in acidic environment |
|                   | Both, Amiodarone and its major active metabolite contribute to observed overall hepatotoxicity | MDR1 possibly plays a role in elimination of amiodarone (induced in rat) | End-stage liver disease occurs rarely in human probably due to repair | Amiodarone complexes with phospholipids and inhibits intralysosomal phospholipase A resulting in accumulation of phospholipids |
|                   | | Mdr2 expression progressively decreases upon amiodarone treatment | | | | | | |
## Table 5 continued

| Training compound | Phase I | Phase II | Phase III and BSEP inhibition | Cell death | Mitochondrial dysfunction | Lysosomal dysfunction and phospholipidosis | Immune response | Association studies |
|-------------------|---------|----------|-------------------------------|------------|--------------------------|-------------------------------------------|------------------|---------------------|
| **Bosentan**      | Metabolites are reported to inhibit rat BSEP | Prototypical inhibitor of BSEP dependent transport | At low concentrations apoptosis by mechanisms related to MPT induction | DF induces mitochondrial permeability transition (MPT) | Immune cell activation by 5-hydroxy-DF and DF-2,5-quinoneimine in mice; DF and DF-AC no immune cell activation | Immune cell activation by UGT2B7*2, CYP2C8, and ABCC2 polymorphisms: increased formation of reactive DF metabolites | GWAS study: association UGT2B7; no HLA association | Association GSTM1 and T1-null genotype |
|                   | Reactive metabolites + are formed, but not thought to play a role through the formation of ROS | Substrate (MRP2) and stimulates MRP2 activity, uncoupling bile dependent (BSEP) and independent (MRP2) flow inducing cholestasis | When a large proportion of the mitochondria are affected, necrotic cell death can occur | 4’hydroxy DF, DF-AC and DF glutathione thioester are stronger inhibitors of ATP synthesis compared to DF | Hepatic adducts and circulating antibodies in patients with hepatotoxicity | No mitochondrial toxicity observed in HepG2 gal-glu assay at low concentrations |
| **CYP3A4 and CYP2C9 dependent metabolism** | UGT1A1 dependent metabolism and transport | Trans inhibition of BSEP ruled out | Metabolism related cell death in rat hepatocytes → inhibition of CYP activity reduced cell toxicity while inhibition of UGT aggravated the toxicity | DF induces mitochondrial permeability transition (MPT) and to a lesser extent by BCRP | | | |
| **Diclofenac**    | Oxidation of DF at 4’ position by CYP2C9 major oxidative route | Glucuronidation is major route → diclofenac acetyl-glucuronide (DF–AC), mainly by UGT2B7 but also by UGT1A9 and 1A6 | At low concentrations apoptosis by mechanisms related to MPT induction | DF is efficiently transported by human Bcrp1 and to a lesser extent by BCRP | Immune cell activation by 5-hydroxy-DF and DF-2,5-quinoneimine in mice; DF and DF-AC no immune cell activation | | GWAS study: association UGT2B7; no HLA association | |
|                   | Minor route is 5-OH-D formation by CYP3A4 | Subsequent hydroxylation of DF–AC by CYP2C8 results in 5-hydroxy acetyl-glucuronide formation | When a large proportion of the mitochondria are affected, necrotic cell death can occur | DF–AC, hydroxy acetyl-glucuronides as well as 4’hydroxy and 5-hydroxy diclofenac are excreted into bile by ABCC2 | | | |
|                   | Both 4’OH-DF and 5OHD-DF form reactive quinone imines, inactivated by GSH | In addition Bcrp1 and Mrp3 are also involved in the biliary excretion and sinusoidal efflux of DF–AC, respectively | | | | | |
|                   | Quinone imines are protein reactive and implicated in redox cycling/ causing oxidative stress | Quinone imines inactivated by GSH S-transferase (GST) catalysed GSH conjugation | | | | | |
|                   | Minor bioactivation pathways result in reactive arene oxide (CYP2C9) and o-imine methide (CYP3A4), inactivated by GSH | DF–AC is protein and GSH reactive GSH conjugation results in a reactive DF-S-acetylglutathione thioester | | | | | |
|                   | Multiple minor oxidative routes result in stable metabolites | DF–AC is protein and GSH reactive GSH conjugation results in a reactive DF-S-acetylglutathione thioester | | | | | |
|                   | NQO1 and NQO2 reduce QIs back to the OH– metabolites | Quinone imines inactivated by GSH S-transferase (GST) catalysed GSH conjugation | | | | | |
| **Flucloxacillin**| Oxidation of the 5-methyl group in the isoxazole ring to a 5-hydroxymethyl derivative by CYP 3A4 | An inhibitor of BSEP | Activates CD4+ and CD8+ T cells in patients with DILI | Flucloxacillin hydroxylation of the 5-methyl group in the isoxazole ring to a 5-hydroxymethyl derivative by CYP 3A4 | Activates CD4+ and CD8+ T cells in patients with DILI | | |
|                   | | | Drug-specific CD8+ T cell response HLA-B*57:01 restricted | | Drug-specific CD8+ T cell response HLA-B*57:01 restricted | | | |
|                   | | | GWAS study showed HLA-B*57:01 as major determinant of DILI | | | | |

**Table 5** continued
| Training compound | Phase I | Phase II | Phase III and BSEP inhibition | Cell death | Mitochondrial dysfunction | Lysosomal dysfunction and phospholipidosis | Immune response | Association studies |
|-------------------|--------|---------|-----------------------------|-----------|-------------------------|---------------------------------------------|----------------|-------------------|
| Fialuridine       | FIAU to FMAU to FAU (via thymidylate synthase)—FMAU also has activity against mtDNA following phosphorylation | Unknown glucuronide conjugates reported | Localized to mitochondria via hENT1 | Inhibition of mitochondrial DNA polymerase γ by the triphosphate metabolite → depletion of mtDNA | Loss of mtDNA encoded proteins leads to loss of function of mitochondrial respiratory chain | | | |
| Nefazodone        | Metabolized to active hydroxynefazodone, m-chlorophenylpiperazine and triazoledione | Metabolites are finally eliminated as glucuronide or sulphate conjugates | Strong inhibition of BSEP Inhibits the efflux activity of MDR1 | Apoptotic cell death | Mitochondrial dysfunction and subsequent apoptotic HepG2 cell death in addition to marked cytosolic calcium increase Inhibition of mitochondrial respiratory complex I and IV, associated with accelerated glycolysis → mitochondrial membrane potential collapse, GSH depletion and oxidative stress | | | |
| Perhexiline       | Hydroxylation by CYP2D6 (highly polymorphic, 10–20-fold inter-individual variability) | Secondary metabolism to dihydroxy-metabolites and glucuronide conjugates | No reports of interaction | Protonated perhexiline accumulates in mitochondrial membrane, leading to multitude of effects, incl. uncoupling of mitochondrial oxidative phosphorylation, inhibition of complexes I and II, decreased ATP formation and reduced mitochondrial β-oxidation of long-chain fatty acids → tri-glyceride accumulation and microvesicular steatosis and/or cell death | Non-covalent complexes of protonated perhexiline with phospholipids are formed which inhibit the action of intralysosomal phospholipases resulting in accumulation of phospholipids along with lysosomal accumulation of the drug | | | |
| Training compound | Phase I | Phase II | Phase III and BSEP inhibition | Cell death | Mitochondrial dysfunction | Lysosomal dysfunction and phospholipidosis | Immune response | Association studies |
|-------------------|---------|----------|-------------------------------|------------|--------------------------|------------------------------------------|---------------|---------------------|
| Tolcapone         | Several metabolites derived from reduced drug at 5-nitro oxidation of amine and acetylamine by several P450s (CYP2E1, 1A2) reactive species that could be trapped with glutathione (GSH) Oxidative hydroxylation of the methyl group by CYP3A4 and to the carboxylic acid is a minor pathway CYP2C9 as major P450 in hydroxylation of tolcapone | The major early and most abundant metabolite is 3-O-β-d-glucuronide conjugate; UGT polymorphism The major late metabolite in plasma is 3-O-methyltolcapone (methylated by COMT) N-acetylamino glucuronide in urine and faeces | Modest inhibition of MRP3, MRP4 and BSEP | Uncoupling of oxidative phosphorylation |
| Troglitazone      | Reactive metabolites formation, including quinones and quinone methides, catalysed by CYP3A potentially leading to toxicity | Mainly glucuronidation and sulfation leading to relatively stable metabolites | Inhibition of the BSEP transporter by troglitazone and its troglitazone sulfate Troglitazone sulfate inhibits OATP and is toxic at similar concentrations as the parent compound € | Induce apoptotic cell death in human hepatocytes at high concentrations by by €! effects on mitochondria resulting in depletion of ATP and release of cytochrome c | Induces mitochondrial membrane permeability in isolated mitochondria € | Lipid peroxidation and PPARγ-dependent steatosis |
| Ximelagatan        | Stepwise esterase-mediated hydrolysis and N-reduction (and vice versa) Outer mitochondrial membrane enzymes—mitochondrial reducing component 1 and 2 (mARC1 and mARC2) involved in melagatan formation | No phase II metabolism reported | Potential involvement of Pgp transport metabolism Transport of intermediates thought to be greater than for parent | Cell viability: tolerated well up to at least 200 uM (ATP content) Apoptosis: after exposure of HepG2 cells at 100 uM for 24 h | Toxicity in vitro via mitochondrial mechanism: 1. higher mitochondrial concentrations of melagatan (mARC) 2. asymptomatic hepatic stress (e.g. virus/ inflammation) leads to mitochondrial stress Mitochondrial functions: no effects | | |
critical intracellular macromolecules leading to toxicity or further interaction with hepatoprotective entities such as glutathione (GSH). CRMs are typically electron deficient molecules (electrophiles) and if not detoxified these electrophiles react with electron rich macromolecules such as proteins, nucleic acids and lipids with the potential to cause a change in biochemical function, or modified such that these modified proteins are processed by the immune antigen presenting cells. CRMs include quinone-imines, quinones, epoxides and reactive oxygen species and other free radicals. Most CRMs are short-lived leading to cellular injury close to the site of formation, but less reactive species can diffuse to other surrounding cells and intracellular organelles depending on concentration, rate of formation of reactive metabolites and the nature of species formed, i.e. hard and soft electrophiles, such as quinones and quinine methides, respectively. Free radicals, by contrast, do not covalently interact with macromolecules, but pair with other free radicals forming covalent bonds with abstraction of hydrogen from neutral molecules to form a new free radical cation.

**Acetaminophen (mechanisms 1, 2, 5)**

The association of reactive metabolite formation and APAP toxicity is among the most documented example of drug liver injury (Bessems and Vermeulen 2001). At normal therapeutic doses, APAP is considered safe, but at high doses it is hepatotoxic and accounts for a large proportion of drug-related morbidity in humans (Jaeschke 2015). Registered annual percentage of acetaminophen-related acute liver failure rose from 28 % in 1998 to 51 % in 2003 in multicentre US study (Larson et al. 2005). At therapeutic doses, APAP is conjugated to form the sulphate and glucuronides metabolites and accounts for 40 and 20–40 % of the dose, respectively, in human. GSH conjugation accounts for less than 15 %. Because of cofactor limitation, at high doses of APAP, oxidative metabolism by CYP2E1, 1A2, 2D6, and 3A4 to the cytotoxic N-acetyl-p-aminquinone-imine (NAPQI) becomes more important (James et al. 2003a; McGill and Jaeschke 2013). NAPQI can be reduced by NAD(P)H:quinone oxidoreductase 1 (NQO1) (Powis et al. 1987; Moffit et al. 2007),
NAD(P)H:quinone oxidoreductase 2 (NQO2, unpublished) or GSH and be conjugated to GSH resulting in the formation of 3-glutathionyl-paracetamol (APAP-SG) (Coles et al. 1988). Following depletion of GSH, NAPQI reacts increasingly with macromolecules causing subsequent hepatic necrosis. In certain individuals, APAP toxicity can arise with therapeutic doses (Vuppulanchi et al. 2007) and this ‘idiosyncratic’ response in liver injury may likely act as a contributing factor to the differences in the expression and activity of the phase I enzymes.

NAPQI interacts with protein thiols, by covalent binding and thiol-oxidation, including the plasma membrane Ca$^{2+}$-ATPase causing an increase in cytosolic Ca$^{2+}$ concentrations, to the actin skeletal structure and function and cell death by centrlobular hepatic necrosis. Covalent binding to critical cellular proteins has been postulated to be the main mechanism of toxicity (Hinson et al. 1995; Pumford and Halmes 1997) in animal species and man. However, the meta-isomer of APAP, N-acetyl-meta-aminophenol (AMAP), appears to covalently bind with proteins at levels similar to APAP, but without toxicity in mice or hamster, yet still it forms the analogous reactive metabolite in rat and human precision-cut liver slices. It appears that AMAP covalently binds and inactivates CYP2E1 in mice, which contrasts the macromolecular covalent binding associated with NAPQI and ensuing necrosis located in the centrlobular region of the liver (Salminen et al. 1998; Hadi et al. 2013). While covalent binding has been attributed to the toxicity of NAPQI, mitochondrial dysfunction as a consequence of APAP toxicity suggests a role of NACQI-targeted mitochondria through modification of proteins associated with the electron transport chain, namely complex V, in addition to nitraed residues on Complex 1 in response to oxidative stress in mice (Qiu et al. 2001; Liu et al. 2009). More recently, APAP was shown to up-regulate the electron transport chain protein expression, possibly in response to oxidative stress and presence of unstable adducts with cysteinyl thiol groups (Stamper et al. 2011).

Studies also suggested a role of the innate immune system in APAP toxicity (Jaeschke et al. 2012). Pro- and anti-inflammatory cascades are simultaneously activated, and their balance plays a major role in determining the progression and severity of APAP-induced hepatotoxicity. A number of modulators of inflammatory responses have been described that can alter the severity of liver injury following the initiation of toxicity. Up-regulation of TNF$\alpha$ and IL-1$\alpha$ occurs in the acetylaminophen-treated mouse. However, the role of TNF$\alpha$ in APAP toxicity is somewhat controversial (Boess et al. 1998; Simpson et al. 2000). Other pro-inflammatory cytokines: interleukin one beta (IL-1$\beta$) and interferon gamma (IFN$\gamma$) have also been examined in APAP toxicity (Blazka et al. 1995; Ishida et al. 2002; James et al. 2003b; Gardner et al. 2003). It was shown that depletion of interleukin (IL-6) resulted in increased sensitivity to APAP (Masubuchi et al. 2003). Chemokines, e.g. macrophage inhibitor protein 2 (MIP-2), also play a role in acetylaminophen-induced toxicity and are up-regulated in APAP toxicity (Lawson et al. 2000).

Intracellular signalling mechanisms also play a role in APAP toxicity: the c-Jun N-terminal kinases (JNKs), a subfamily of the mitogen-activated protein (MAP) kinases, are activated by phosphorylation early in APAP toxicity (Gunawan et al. 2006; Latchoumycandane et al. 2006; Henderson et al. 2007) and DNA fragmentation is another mechanism that has been implicated in acetylaminophen-induced hepatotoxicity (Salas and Corcoran 1997). Subsequently, it was reported that endonuclease G was important in the acetylaminophen-induced nuclear fragmentation (Bajt et al. 2006).

As described, the hepatotoxicity of APAP appears to occur by a complex mechanistic sequence. Associated with these essential events, there appears to be a number of modulators of inflammatory responses that can alter the severity of liver injury. The threshold and susceptibility to APAP hepatotoxicity is determined by the interplay of injury promoting and inhibiting events downstream of the initial production of toxic metabolite where environmental and genetic control may be of critical importance in determining susceptibility to APAP hepatotoxicity.

**Diclofenac (mechanisms 1, 2, 4)**

Therapeutic use of diclofenac (DF) is associated with rare but sometimes fatal hepatotoxicity with a characteristic delayed onset of symptoms and poor dose–response relationship. Elevated levels of liver enzymes develop in about 15 % of patients that are regularly taking diclofenac and a threefold rise in transaminase levels has been reported in 5 % (Banks et al. 1995). Clinically relevant hepatotoxicity leading to hospital referral occurs in 6.3 per 100,000 diclofenac users (de Abajo et al. 2004).

In contrast to APAP, diclofenac requires initial hydroxylation by CYP2C9 and CYP3A4, or peroxidase-mediated oxidation to form different quinone-imine reactive metabolites from 4’ and 5-hydroxydiclofenac, which in turn can form adducts with macromolecular proteins or form conjugates with GSH (Tang et al. 1999; Madsen et al. 2008b). The parent diclofenac also forms a reactive acyl-glucuronide metabolite with the formation of covalent modification of cellular proteins and the covalent binding to liver proteins in rats, which is linked to the activity of a hepatic canalicular transport protein, Mrp2 (Tang 2003). The acyl-glucuronide and the quinone-imines of diclofenac, derived from metabolic activation of diclofenac, are both implicated in covalent modification of cellular proteins with the disruption of critical cellular functions and/or immunological
response in susceptible patients (Shen et al. 1999; Kenny et al. 2004). Besides GSH conjugation, it has been shown that quinone-imines of 4′ and 5-hydroxydiclofenac can be detoxified by reduction by polymorphic NQO1 as well (Vredenburg et al. 2014).

Besides distinct chemically reactive metabolites, other diclofenac-related hazards have been identified and have been studied. These include oxidative stress generation based on peroxidase-catalysed production of radicals, which in turn can oxidize GSH and NAD(P)H, while molecular oxygen may be reduced and activated or the radicals undergo redox cycling (Galati et al. 2002). Also, mitochondria are a major subcellular target for diclofenac. Diclofenac disturbs in vitro liver mitochondrial function at multiple levels, including the phosphorylating system and mitochondrial permeability transition pore, being associated with increased oxidative stress and apoptotic signalling (Masubuchi et al. 2002; Gómez-Lechón et al. 2003). In high concentrations, diclofenac causes rapid and concentration-dependent ATP depletion. Diclofenac decreases the mitochondrial transmembrane potential by direct effects on the mitochondrial inner membrane, uncoupling of respiration by proton shuttling or opening of the mitochondrial membrane permeability transition pore. In HepG2 cells, TNFα enhances hepatocyte injury caused by diclofenac (Fredriksson et al. 2011). Diclofenac-mediated stress signalling suppressed TNFα-induced survival signalling routes and sensitizes cells to apoptosis. However, a striking but somewhat sobering conclusion is that we still do not understand the real reasons for the individual susceptibility in patients.

Lysosomal impairment (steatosis and phospholipidosis; mechanism 3)

Microvesicular steatosis or microsteatosis is a form of liver toxicity which is associated with liver failure, pronounced hypoglycaemia and encephalopathy in patients (Farrell 2002; Stravitz and Sanyal 2003). Liver pathology reveals the presence of numerous cytoplasmic lipid droplets, visible by staining with oil red O. Liver triglycerides can accumulate as vacuolar lipid bodies within the hepatocyte by a number of drugs (Farrell 2002; Labbe et al. 2008) and frequently referred to as non-alcoholic fatty liver (NASH), which is most frequently observed in obese, diabetic patients and related disorders. Progression from fibrosis to cirrhosis can occur rapidly. Drugs responsible for this hepatic lesion can also induce a mixed form of fat accumulation with macrovacuolar steatosis and microvesicular steatosis occurring in anatomically adjacent hepatocytes, the formation of which may depend on proteins such as perilipin and adipophilin associated with lipids and possible presence of free fatty acids (Fromenty and Pessayre 1995). The mechanisms associated with macrovacuolar and microvesicular steatosis remain to be confirmed, but steatosis arises from either an increased availability of free fatty acids to the liver and stimulation of de novo hepatic lipogenesis (Begriche et al. 2006; Moreau et al. 2009). Drugs known to cause steatosis can be broadly divided into those with steatosis and steatohepatitis with well-characterized mechanisms of hepatotoxicity, for example, amiodarone, fialuridine and perhexiline. Other drugs form less well-defined mechanisms include latent forms of NASH, such as tamoxifen, and episodic cases of steatosis and steatohepatitis, such as carbamazepine.

Cationic amphiphilic compounds comprise a lipophilic moiety and amine group, the latter of which becomes protonated as the drug crosses from the cytosol into the acidic milieu of lysosomes or crosses the outer membrane of the mitochondrion into the acidic inter-membrane space where the uncharged drug is subsequently protonated and unable to pass back across the membrane as the positively charge species. As a consequence of the charge distribution, drug accumulates in lysosomes as the positively charged drug forming noncovalent complexes with phospholipids (Fig. 3.3). As the drug-phospholipid complexes are not degraded, these complexes progressively accumulate in the form of myelin structures of enlarged lysosomal bodies. The clinical pathology of cationic amphiphilic accumulation of drugs, as phospholipids, leads to the common occurrence of phospholipidosis in patients, yet the clinical consequences of which appears with limited clinical symptoms. By contrast, cationic amphiphilic drugs crossing the outer mitochondrial membrane are protonated and through the electrochemical gradient pass to the inner mitochondrial matrix where these drugs accumulate targeting processes of mitochondrial function linked with e-transport chain and fatty acid metabolism.

Amiodarone (mechanisms 1, 3)

Amiodarone is a cationic amphiphilic lipophilic compound (Atiq et al. 2009) with the propensity to accumulate in the lipid-rich environment of organelles affecting both mitochondrial and lysosomal function and thus causes liver damage by a number of mechanisms: microvesicular steatosis, concomitant macrovacuolar steatosis and steatohepatitis, and phospholipidosis. Elevated blood levels of liver enzymes have been recorded in 14–82 % of patients (Lewis et al. 1989).

As a consequence of the charge distribution from cytosol to the acidic milieu, amiodarone accumulates and inhibits phospholipase activity through one of two mechanisms: firstly, by formation of noncovalent complexes with phospholipids in lysosomes and as the drug-phospholipid complexes are not degraded, these complexes progressively
accumulate as described above (Pirovino et al. 1988), leading to phospholipidosis; secondly, amiodarone and its metabolites (e.g. N-desmethylamiodarone) accumulate in lysosomes of parenchymal, bile duct epithelium and kupffer cells with inhibition of the metabolism of lysosomal lipids by phospholipases A1 and A2 leading to phospholipidosis (Heath et al. 1985).

Phospholipidosis can occur within 2 months of starting amiodarone therapy (Capron-Chivrac et al. 1985; Rigas et al. 1986) and occurs in a higher percentage of patients receiving amiodarone than the incidence of hepatocellular damage (Atiq et al. 2009), suggesting amiodarone-induced phospholipidosis may only have a contributory role towards the more serious consequences of amiodarone-induced hepatotoxicity and cirrhosis. Therefore, diagnosis of phospholipidosis in patients serves as a biomarker for the accumulation of amiodarone (Atiq et al. 2009) rather than as a biomarker for the more serious forms of amiodarone hepatotoxicity.

With formation of enlarged lysosomal bodies, the release of proteolytic enzymes from aberrant lysosomes is a mechanism likely attributed to amiodarone-induced liver damage (Guigui et al. 1988; Yagupsky et al. 1985; Lewis et al. 1990). With the seepage of proteolytic enzymes over prolonged periods, the proteolytic enzymes may in turn contribute to the elevation of aminotransferases leading to hepatic necrosis, fibrosis, and cirrhosis of the liver.

Amiodarone-induced inhibition of cellular respiration is another possible pathogenic mechanism for amiodarone-induced liver damage. Impairment of mitochondrial β-oxidation and uncoupling of oxidative phosphorylation leads to the formation of reactive oxygen species, which in turn has a role in the development of amiodarone-induced cirrhosis (Fromenty et al. 1990a, b).

In addition to the usual pathologic findings of cirrhosis, leucocytic infiltrate and high Mallory’s hyaline (Mallory’s bodies) are suggestive of amiodarone-induced cirrhosis together with the presence of phospholipid-rich lamellar lysosomal inclusion bodies (Lewis et al. 1990).

Although amiodarone hepatotoxicity is serious and potentially fatal, such effects are rare. Asymptomatic liver enzyme elevation occurs in 25 % of the population treated with amiodarone (Lewis et al. 1989) and is usually reversible upon discontinuation of therapy (Pol lakk 2010). Symptomatic hepatic dysfunction occurs in less than 1 % of the population treated with amiodarone. Besides chronic liver injury which includes steatosis (macro and microvesicular steatosis) and cirrhosis due to prolonged amiodarone use, acute hepatic side effects (idiosyncratic reaction may be involved in pathogenesis) from amiodarone intravenous loading dose have been reported (Rätz Bravo et al. 2005).

**Perhexiline (mechanisms 3, 4)**

Perhexiline is an anti-anginal drug, which despite its efficacy diminished in its use due to a small number of cases of severe hepatotoxicity and neurotoxicity. Perhexiline is mainly metabolized by the polymorphic CYP2D6 in the liver, and these side effects were related to high plasma concentrations with standard doses in poorly metabolizing patients (Wright et al. 1973; Shah et al. 1982).

At high concentrations, protonated perhexiline rapidly accumulates in mitochondria along the mitochondrial membrane potential as an amphiphilic (or amphipathic) molecule. A multitude of effects on mitochondria have been reported, including the uncoupling of mitochondrial oxidative phosphorylation, inhibition of complexes I and II, and decreased ATP formation. The most evident effect was fatty acid metabolism inhibition (Ashrafan et al. 2007). Most importantly, characteristic lamellar lysosomal inclusion bodies representing phospholipidosis as well as triglyceride and fatty acid accumulation were identified.

**Cholestasis, inhibition of biliary efflux and BSEP (mechanism 4)**

Cholestatic and mixed cholestatic and hepatocellular injury are forms of severe DILI in man. Recent evidence of drugs secreted into the bile suggests these drugs are primary candidates inducing cholestatic liver disease in patients, but do not induce hepatotoxicity in rats. The flow of bile is highly regulated through several basolateral and canalicular transport proteins such as Na⁺-dependent taurocholate transport protein, BSEP and a series of multi-drug resistance associated proteins. Among these transport proteins, BSEP is believed to play a pivotal role for DILI and inhibition of this transport protein leading to cholestatic injury. Bile acid accumulation in hepatocytes as a consequence of BSEP inhibition is proposed as a mechanism for the hepatotoxicity of several drugs including cyclosporine, troglitazone and bosentan (Fig. 3.4). Of those drugs causing cholestasis in patients, several do not cause a similar pattern of cholestatic injury in the rat, but nevertheless inhibit Bsep with reported elevations in the levels of serum bile acids. Explanations for the lack of toxicity in the rat stem from either the inhibition of uptake transport proteins and/ or differences in the inhibitory potential of human BSEP and rat Bsep. Alternative explanations for the lack of hepatotoxicity in the rat are provided by the complement of bile acids comprising the bile acid pool in the liver—rat bile acid composition being more hydrophilic and therefore less toxic than the composition of human bile acids. Nevertheless, the overall interplay and mechanisms of drug-induced cholestasis remain poorly defined. Among
several studies on the role of BSEP hepatocellular injury, two substantive studies link hepatotoxicity to BSEP inhibition. Of those drugs evaluated, 75 % of drugs exhibit IC50 greater than 133 µM and therefore were viewed negative. By contrast, 16 % showed greater inhibition of BSEP with IC50 ≤25 µM (Morgan et al. 2010) and in a further study, 17 of 85 drugs with an IC50 <100 µM and Cmax,u >2 nM are known to cause DILI in man (Dawson et al. 2012). Both these studies, and others, conclude that BSEP inhibition plays a role in cholestatic injury in patients.

**Bosentan (mechanism 4)**

The proposed mechanism of bosentan-induced cholestasis is presently thought to be mediated, at least in part, by inhibition of BSEP activity and is among one of the more extensively investigated drugs to inhibit BSEP. The mechanism of bosentan-induced liver injury in patients is believed, at least in part, to be mediated inhibition of the canalicular bile transport protein BSEP with accumulation of bile acids as the prevailing mechanism in the aetiology of bosentan-induced liver injury in patients (Fattinger 2001). Consistent with this, proposed mechanism is the observed inhibition of BSEP in vitro models and the incidence of dose-related liver injury in patients, which is reversible with reduction of daily dose (Noé et al. 2002; Mano et al. 2007). The inhibition of BSEP is further supported by clinical observations demonstrating the increase in serum bile acids and the toxicity of bosentan is more commonly observed in patients co-treated with glyburide, a known inhibitor of BSEP (Stieger et al. 2000). Bosentan is mainly eliminated by hepatic metabolism and subsequent biliary excretions of three metabolites formed by CYP 2C9 and 3A4 (Pichler et al. 1988) with no evidence of reactive metabolite formation.

The intravenous administration of bosentan to rats increases the level of serum bile acids suggesting the rat as a possible model for the study of BSEP inhibition and hepatotoxicity in man (Fattinger 2001). However, treatment of rats with bosentan does not cause liver injury where a basolateral compensatory role of Ntcp, expressed more than human NTCP, contributes to the sinusoidal transport of bile acid elimination and a reduction in intracellular accumulation of bile acids in the liver of rats (Hagenbuch and Meier 1994). In the rat, bosentan is a more potent inhibitor of Ntcp than the human NTCP in suspensions of hepatocytes and in vesicles expressing Ntcp and NTCP proteins with mechanisms of non-competitive and competitive inhibition, respectively (Leslie et al. 2007). Mild forms of bosentan-associated liver toxicity occurs in approximately 10 % in patients within 6 months, but less frequently serious liver toxicities are reported and are often associated with co-morbidities (Eriksson et al. 2011).

The idiosyncratic nature of bosentan; delay of onset, role of comorbidities and variable extent of the mild to severe forms of liver toxicities and perceived mechanism of bosentan-induced liver toxicity was selected as the a priori training compound for inclusion for the study of BSEP and drug transport studies.

Nefazodone, troglitazone, diclofenac, tolcapone and perhexiline are among a number of other drugs selected as training compounds with implications for the inhibition of bile transport proteins.

**Tolcapone (mechanisms 2, 4)**

Tolcapone is a selective and reversible inhibitor of the enzyme catechol-O-methyl transferase (COMT) and is used as an effective adjunct to levodopa/carbidopa in the treatment of Parkinson’s disease. However, tolcapone is under strict regulations on liver enzyme monitoring due to the hepatic failures that appeared, three of them with fatal outcome. In 1998, tolcapone was actually withdrawn from the European Union (EU) and Canadian markets due to liver problems, but it is again reintroduced to EU. Liver function elevations above the upper limit of normal (ULN) occurred in 20.2 and 27.5 % of patients in the placebo and active treatment groups, respectively; increases ≥3 times the ULN occurred in 1.2 and 1.7 % of patients (Lees et al. 2007).

The mechanism of hepatotoxicity introduced by tolcapone is still not well understood, but it seems that tolcapone is able to cause mitochondrial uncoupling of OXPOS and to disrupt the energy-producing cycle (Haasio et al. 2002a, b). This leads to a decreased ATP production and increased oxygen consumption as a compensatory function of the cell, and ultimately cell death may take place. Uncoupling of OXPOS is reflected as a rise in body temperature since the energy is released as heat and liver damage is induced due to mitochondrial toxicity (Terada 1990).

Tolcapone has been reported to be toxic to human neuroblastoma cells and caused a profound reduction in ATP synthesis mirroring the effects of a classical uncoupler (Korlipara et al. 2004). However, the same study showed that tolcapone markedly inhibits ATP synthesis in cultured cells devoid of mtDNA and therefore, a functional respiratory chain. Tolcapone-induced hepatotoxicity could also be related to elevated catecholamine levels in patients which receive other drugs with adrenergic receptor-mediated toxicity (Rojo et al. 2001). The mechanism of tolcapone toxicity may thus also involve mechanisms independent of its effects on OXPHOS.

It has also been speculated that the different metabolism of second-generation COMT inhibitors might be responsible for the toxicity observed. Metabolism of tolcapone into amine or acetylamine metabolites in humans can...
be followed by oxidation to reactive oxygen species and induce hepatocellular injury. The same oxidative metabolites are not found in humans treated with entacapone (Smith et al. 2003). Also, mutations in the uridine diphosphate-glucuronosyltransferase 1A9 gene which encodes for the enzyme which metabolizes tolcapone and thereby might promote enhanced COMT activity showed increased occurrence of hepatic dysfunction (Martignoni et al. 2005). Besides the effect on OXYPHOS, tolcapone is reportedly an inhibitor of BSEP transporter with comparatively higher value of IC50 than several more potent inhibitors of BSEP activity in vesicle systems (Morgan et al. 2010).

**Nefazodone (mechanisms 2, 4)**

Nefazodone is a triazolopyridine antidepressant withdrawn from the market due to the significant number of reports of nefazodone-mediated hepatic injury (Stewart 2002; Choi 2003). Described clinical symptoms were jaundice and increases in ALT (10×), AST (10×), total bilirubin (mostly conjugated), and prothrombin time. Histological liver evaluations demonstrated centrilobular necrosis, bile-duct proliferation with cholestasis (Lucena et al. 1999). The incidence was reported 1 in 250,000–300,000 patients-years of exposure and the onset of injury varied from 6 weeks to 8 months. Although the exact mechanism of hepatotoxicity remains unknown, several possible mechanisms have been described in the literature.

It has been shown that clinical hepatotoxicity of nefazodone is linked to the ability of drug to inhibit bile acid transport (Kostrubsky et al. 2006). Nefazodone induces a strong inhibition of BSEP and taurocholate efflux in human hepatocytes, and 1 h after oral drug administration transitory increase in rat serum bile acids was observed (Kostrubsky et al. 2006).

Mitochondrial impairment is likely to contribute to nefazodone hepatotoxicity (Dykens et al. 2008). In isolated rat liver mitochondria and in intact HepG2 cells, nefazodone inhibits mitochondrial respiration. Using immunocaptured oxidative phosphorylation complexes, complex I, and to a lesser amount complex IV were identified as the targets of toxicity associated with accelerated glycolysis. Bioactivation of nefazodone and formation of reactive intermediates have also been described. Nefazodone incubations with microsomes or recombinant CYP3A4 in the presence of sulphhydryl nucleophiles showed formation of thiol conjugates of mono-hydroxylated nefazodone metabolite (Kal-gutkar et al. 2005).

**Troglitazone (mechanisms 1, 2, 3, 4)**

Troglitazone was the first thiazolidinedione anti-diabetic drug that was removed from the market due to reported cases of increase in ALT and 1 in 40,000 patients with reported liver failure (Faich and Moseley 2001). In clinical trials, 1.9% of the subjects had elevations of $\geq 3 \times$ ULN of ALT concentrations and reported cases of overt liver injury and jaundice (Watkins 2005).

Formation of reactive intermediates, including quinones and quinone methides, is hypothesized to be responsible for troglitazone hepatotoxicity through either GSH depletion/covalent binding mechanism or via oxidative stress caused by redox cycling of the quinone. However, there was no correlation of the generation of the reactive metabolites with susceptibility to troglitazone cytotoxicity, and chemical inhibitors of drug metabolizing enzymes in in vitro could not protect the cells against the toxicity (Kostrubsky et al. 2000; Tettey et al. 2001). Therefore, metabolic activation of troglitazone is not apparently the primary mechanism of hepatotoxicity. Several other mechanisms have been described.

Troglitazone induces cytotoxicity in hepatocytes from numerous species including humans. A major non-metabolic toxicity factor is via effects on mitochondria resulting in depletion of ATP and release of cytochrome c, which induces cell death via apoptosis (Tirmenstein et al. 2002; Hu et al. 2015). Lipid peroxidation and PPARγ-dependent steatosis are also mediated by troglitazone. Troglitazone induced PPARγ levels selectively in the liver under pathophysiological conditions, and severe steatosis may result in the accumulation of the drug in lipid-rich hepatocytes, with subsequent lipid peroxidation, and predispose the liver to the development of fibrosis (Bedoucha et al. 2001; Boelsterli and Bedoucha 2002). Susceptibility to liver injury in individuals has been attributed to explain the distinct sensitivity of patients to troglitazone. It has been shown that diabetics, obese individuals, and other persons with impaired liver function, were more likely predisposed to troglitazone toxicity due to decreased ability to eliminate the drug, compromised mitochondrial function in the liver cells, bile salt retention and steatosis, and/or underlying inflammatory status of the liver in diabetic subjects.

Other mechanisms linked to mechanisms of hepatotoxicity are the inhibition of the BSEP transporter by troglitazone and its metabolite, troglitazone sulphate, with the accumulation of toxic bile salts in the liver cells, cholestasis and apoptosis through the Fas death receptor signalling pathway (Funk et al. 2001; Yang et al. 2014). Inhibition of BA transport by troglitazone and its major metabolite, troglitazone sulphate, has recently been shown through use of Quantitative Systems Pharmacology (QSP) to predict delayed hepatotoxicity in humans due to hepatocellular accumulation of toxic bile acids and drug exposure, and species differences attributable to the pathophysiology of bile acids (Yang et al. 2014).
Adaptive immunity (mechanism 5)

It is clear from the literature that immune responses and associated autoimmunity play an important role in both predictive (acute) and idiosyncratic DILI (Fig. 3.5). There is an increased weight of evidence for the role of immune cells (lymphocytes, macrophages, and neutrophils) in hepatic pathology.

Although hepatic inflammation is a common finding in drug-induced liver toxicity, the classic immune-allergic or hypersensitivity reactions are generally found in only a minority of DILI patients. The inflammatory phenotype has been attributed to the innate immune response generated by Kupffer cells, monocytes, neutrophils, and lymphocytes. The adaptive immune system is also influenced by the innate immune response leading to liver damage. Drugs that cause idiosyncratic DILI associated with fever, rash, a relatively short period of therapy before the onset of DILI and a rapid onset on re-challenge fit into the immune idiosyncrasy category.

Ximelagatran (mechanism 5)

Ximelagatran was the first oral direct thrombin inhibitor that reached the market for short-term use in the prevention of venous thromboembolism and was assessed for the prevention and treatment of a range of thromboembolic disorders for chronic use. Pre-clinical and toxicological studies provided no indication of ximelagatran affecting hepatic functions. Also, in short-term prophylaxis, there was no increase in the incidence of liver enzyme elevations with ximelagatran. However, clinical trials with long-term (>35 days) treatment with ximelagatran showed increased rates of liver enzyme elevations (Wallentin et al. 2003; Schulman et al. 2003; Olsson 2003; Lee et al. 2005; Albers et al. 2005; Fiessinger et al. 2005). The clinical pattern of events suggests hepatocellular damage. The combination of ALT >3 ULN and total bilirubin ≥2 ULN was 0.5% among patients treated with ximelagatran (Keisu and Andersson 2010). Return of ALT to normal was documented in the majority of patients whether treatment was maintained or discontinued, suggesting an adaptive mechanism. Extensive in vitro studies at the molecular, subcellular and cellular level have not been able to define mechanisms explaining the pattern of hepatic injury observed in these long-term clinical trials (Kenne et al. 2008).

Previously reported mechanisms of drug-induced hepatotoxicity are unlikely to explain the observed ALT elevations in ximelagatran exposed individuals: ximelagatran metabolism does not involve the CYP450 system and does not form reactive metabolites, no effects have been observed below 100 μM ximelagatran when investigating cell viability, mitochondrial function, calcium homeostasis, apoptosis, cytoskeleton, reactive oxygen species, GSH levels, bile acid transporters and nuclear receptors. The knock down of mARC2, the enzyme that reduces ximelagatran, has recently illustrated that the mitochondrial toxicity is strongly inhibited, suggesting a component of metabolic activation and decrease in GSH levels (Neve et al. 2015).

A possible immunogenic pathogenesis, a strong genetic association between elevated ALT and the major histocompatibility complex (MHC) alleles DRB1*07 and DQA1*02 was discovered and replicated, suggested an underlying immune-related mechanism but with no clinical signs of immunopathology (Kindmark et al. 2008).

Dabigatran etexilate is another novel direct thrombin inhibitor DTI proven to be effective and liver-friendly in various randomized controlled clinical trials mainly in the settings of venous thromboembolism and atrial fibrillation (Ma et al. 2011). Although not formally on the list of negative controls, it is used in some of the MIP-DILI experiments as a comparison for ximelagatran.

Flucloxacillin (mechanism 5)

Flucloxacillin is a β-lactam antibiotic, used as the first line treatment for Staphylococcal infections. Common use of drug induced cholestatic liver injury in 8.5 in 100,000 patients with the delayed onset of clinical symptoms 1–45 days and 1.8 following 46–90 days after starting flucloxacillin therapy (Koek et al. 1994; Dobson et al. 2005; Russmann et al. 2005; Li et al. 2009). The mechanism or mechanisms of cholestasis with bile duct injury and Vanishing Bile Duct Syndrome (ductopenia) are largely unknown, yet small amounts of the compound form metabolites that involved the activity of CYP3A4, which itself may be under genetic control. Whether the formation of these metabolites is directly toxic to cholangiocytes after excretion into bile or formed in cholangiocytes is not yet known. It is generally accepted that an immune-mediated response subsequently accounts for the development of the directly or indirectly linked genetic pre-disposition of DILI, but the mechanisms are still to be conclusively determined.

Strong HLA association with DILI and activation of CD8+ T cells isolated from patients with DILI are suggestive for adaptive immune activation. HLAB*57:01 genotype carriers have an approximately 80-times higher risk (odd ratios = 80.6) of flucloxacillin-induced DILI, but not all carriers will develop DILI (Daly et al. 2009). Evidence showed that reactions to flucloxacillin are driven by drug-specific activation of CD8+ T lymphocytes. Flucloxacillin-responsive CD4+ and CD8+ T cells from patients with DILI have been characterized and shown that naive CD8+ T cells from volunteers expressing HLA-B*57:01 are activated with flucloxacillin (Monshi et al. 2013). Covalent
modification of flucloxacillin is thought to be a prerequisite for flucloxacillin-induced liver injury (Carey and Van Pelt 2005). Flucloxacillin modifies specific lysine residues on human serum albumin (Monshi et al. 2013). However, relationship between adduct formation in liver, immune activation and liver injury not defined yet.

Flucloxacillin DILI is the only model of idiosyncratic immune-mediated DILI with patient data to confirm an immune pathogenesis.

Negative control compounds

Buspirone, entacapone, metformin and pioglitazone were proposed as negative controls. Some are structural analogues of training compounds with less or no toxic effects at the therapeutic dose when compared to the matched positive training compound. Others are not structural analogues, but do address the same pharmaceutical target without evidence of known liver toxicity.

It is important to mention that probably no compound is a ‘true negative’ with regard to cellular toxicity and dose. Equally, no compound will necessarily target exclusively one pathway, so there will always be ‘biological background’ or multiple toxicological events, and the compensatory mechanisms invoked.

Buspirone

Buspirone, the azaspirodecanedione anxiolytic and antidepressant, is a 5-HT1A receptor partial agonist and a mixed agonist/antagonist on postsynaptic dopamine receptors. Without any reports or clinical observations associated with DILI, it is commonly utilized as negative control drugs (Wu et al. 2016).

Buspirone is a marketed structural analogue of nefazodone, and it is commonly used as its pair in the studies, together with trazadone. Inhibition of canalicular transport with nefazodone has been reported, but not with trazadone or buspirone (Kostrubsky et al. 2006). Accordingly, nefazodone was the most toxic, trazadone had relatively modest effects, whereas buspirone showed the least cytotoxicity and effects on mitochondrial function (Dykens et al. 2008).

Although buspirone, like nefazodone, generates p-hydroxybuspirone in liver microsomes, no sulphhydryl conjugates of this metabolite were observed suggesting that two-electron oxidation of p-hydroxybuspirone to the corresponding quinone-imine is less favourable. It was also observed that the 2-aminopyridine or 2-aminopyrimidine derivatives present a ‘safer’ alternative to aniline-based compounds, which are prone to bioactivation (Kalgutkar et al. 2005), and perhaps confirms the lack of idiosyncratic hepatotoxicity with buspirone in the clinic.

Entacapone

Entacapone is a selective, potent and reversible COMT inhibitor and structural analogue of tolcapone. While tolcapone has not been related to reported cases of associated liver injuries in patients. For this reason, entacapone was selected as a negative training compounds used in the MIP-DILI project.

In clinical use, entacapone has only been reported to induce hepatotoxicity in 3 cases (Fisher et al. 2002). However, in two of these cases, the patients had concomitant medications with hepatotoxic potential, and the third case was reported with a history of long-standing alcohol abuse and alcohol-induced liver cirrhosis.

In vitro assays have shown that entacapone is a weak uncoupler of oxidative phosphorylation at high concentrations, while tolcapone has been reported to be an uncoupler at low micro-molar concentrations (Nissinen et al. 1997; Haasio et al. 2002a). Sets of proteins interacting with entacapone or tolcapone were identified in human cell line HepG2 and rat liver subcellular fractions. The cellular distribution of proteins captured by entacapone was not linked to mitochondrial function, while for tolcapone, a large proportion of proteins were identified to be mitochondrial origin (Fischer et al. 2010). Also, in vivo studies in rats tolcapone were more toxic than entacapone causing high mortality, elevation of body temperature and necrotic changes in liver tissue (Haasio et al. 2001, 2012b).

Difference in toxicity could also be a result of differences in the metabolism of drugs. Amine or acetylamine metabolites that can be followed by oxidation to reactive oxygen species and induce hepatocellular injury by being trapped by GSH to form metabolic adducts were not observed in with entacapone (Smith et al. 2003). Entacapone clearance is also significantly higher than tolcapone clearance in humans (Data from FDA approved labelling). In addition, recent work has demonstrated that both drugs have the potential to alter hepatobiliary transport causing modest inhibition of the BSEP and the basolateral efflux transporters (MRP3 and MRP4) (Morgan et al. 2013).

Metformin

Metformin is an antihyperglycaemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Because metformin is not metabolized in the liver (Sirtori et al. 1978), it has been considered safe from a hepatic liver injury although known cases of cholestasis have been reported (Babich et al. 1998; Desilets et al. 2001; Nammour et al. 2003; Kutoh 2005).
Metformin can promote liver mitochondria injury and predispose to cell death (Carvalho et al. 2008; Bridges et al. 2014). Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically poised HepG2 cells and human hepatocytes in vitro (Dykens et al. 2008). However, human vivo and clinical side effects showed fewer than 10 cases of metformin-induced hepatotoxicity (mixed pattern) (Saadi et al. 2013). These cases are idiosyncratic, usually associated with alcohol or other drugs, and mainly occur in older patients (Kutoh 2005; Cone et al. 2010; Saadi et al. 2013).

**Pioglitazone**

Pioglitazone, a second-generation thiazolidinedione, is commonly used in the management of type 2 diabetes mellitus. Unlike troglitazone, pioglitazone is generally considered safe from a hepatic standpoint and is commonly used as a negative compound for liver toxicity studies. Although case reports of liver injury and failure with pioglitazone have been published (Maeda 2001; May et al. 2002; Nagasaka et al. 2002; Pinto and Cummings 2002; Floyd et al. 2009), the risk of liver failure or hepatitis is not higher than with other oral antidiabetic agents (Rajagopalan et al. 2005; Berthet et al. 2011).

In vitro studies in hepatocyte cultures showed that troglitazone alone among the thiazolidinediones is toxic (Kostrubsky et al. 2000). The difference in the profiles is the presence of the side chain of troglitazone, which might uniquely predispose it among the thiazolidinediones to hepatotoxicity due to the quinone metabolite formation. From electrochemical oxidations of pioglitazone in the presence of GSH, no GSH conjugates could be identified (Madsen et al. 2008a).

Moreover, the observed ALT elevation levels in troglitazone clinical trials, results of studies in hepatocyte cultures and evidence of the distinct metabolic pathway suggest that hepatotoxicity may not be a class effect of the thiazolidinediones but rather a unique effect of troglitazone and that pioglitazone do not share its hepatotoxic profile (Scheen 2001; Tolman and Chandramouli 2003).

**Summary and conclusions**

Training compounds were selected on the basis of clinical evidence of DILI and availability of known mechanisms by which these compounds are believed to cause liver injury. The evidence-based selection of the set of training compounds was subsequently employed systematically for the pharmacological, physiological and toxicological evaluation of model systems to support the translational relevance of these models and improvement of a greater understanding of drug liability’s mechanisms to cause DILI in man. From a total of 40 compounds nominated, 10 training compounds and 4 negative controls were selected.

It is acknowledged at the outset in the selection of drug compounds that our present knowledge of the mechanisms by which drugs are known to cause human DILI remains incomplete. Moreover, through the evidence-based selection of training compounds, many can be regarded as largely imperfect ‘reagents’ to probe, in isolation and selectively, each of the 5 categories of DILI, where many of the drugs reviewed herein neither exhibit a specific biochemical or toxicological target. As such, many if not all drugs in this review appear to exhibit multiple toxicological mechanisms when evaluated in model systems or clinical intelligence (see Fig. 3). Thus it is clear that prediction of DILI in man requires a matrix of multiple test systems and training compounds to afford a deeper understanding of which mechanisms/liabilities are relevant to man. The ‘selection’ of training compounds therefore offers a valuable tool to profile DILI mechanisms and to interrogate existing and novel in vitro systems for the prediction of human DILI. This a priori knowledge of drugs to target more than one mechanism leading to probable DILI also underlies the basis for a more rational integrated approach to the investigation of DILI early in drug discovery to eliminate simple and more complex liabilities through the use of a tiered approach to early safely risk assessment.

Several publications have recently appeared in which the here selected training compounds and negative controls have been investigated in order to substantiate their utility as training compounds to profile and elucidate further DILI mechanisms and to interrogate existing and novel in vitro systems for the prediction of human DILI (Sison-Young et al. 2015; Bell et al. 2016; Sison-Young et al. 2016; den Braver-Sewradyj et al. 2016; den Braver et al. 2016).

**Acknowledgments**

The MIP-DILI consortium is supported by the Innovative Medicines Initiative Grant Agreement Number 115336.

**Authors’ contribution**

SD, RJW and NPEV prepared and wrote the manuscript, and all authors contributed to the revision and approval the final manuscript. Selections of compounds were accomplished through a MIP DILI Workshop held at Servier, Suresnes, France, with contributions from members of the consortium. Affiliations 1-8 are members of the Innovative Medicines Initiative MIP-DILI (Mechanism-based Integrated systems for the Prediction of Drug-Induced Liver Injury) Consortium.

**Open Access**

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

Abboud G, Kaplowitz N (2007) Drug-induced liver injury. Drug Saf 30:277–294

Albers GW, Diener H-C, Frison L et al (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293:690–698. doi:10.1001/jama.293.6.690

Ashrafian H, Horowitz JD, Frenneaux MP (2007) Perihemispheric. Cardiovascular Drug Rev 25:76–97. doi:10.1111/j.1527-3466.2007.00006.x

Atiq M, Davis JC, Lamps LW et al (2009) Amiodarone-induced liver cirrhosis. Report of two cases. J Gastrointest Liver Dis 18:233–235

Babich MM, Pike I, Shiffman ML (1998) Metformin-induced acute hepatitis. Am J Med 104:490–492. doi:10.1016/S0002-9343(98)00088-6

Baji ML, Cover C, Lemaisters JJ, Jaeschke H (2006) Nuclear translocation of endonuclease G and apoptosis-inducing factor during acetaminophen-induced liver cell injury. Toxicol Sci 94:217–225. doi:10.1093/toxsci/kfl077

Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology 22:820–827

Bedoucha M, Atzpodien E, Boelsterli UA (2001) Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35:17–23

Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6:1–28. doi:10.1016/j.mito.2005.10.004

Bell CC, Hendriks DFG, Moro SML et al (2016) Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep 6:25187. doi:10.1038/srep25187

Berthet S, Olivier P, Montastruc J-L, Lapeyre-Mestre M (2011) Drug-induced toxicity: molecular and biochemical mechanisms, anaphages and protective approaches. Crit Rev Toxicol 31:55–138

Bessems JG, Vermeulen NP (2001) Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 31:55–138

Blazka ME, Wilmer JL, Holladay SD et al (1995) Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 133:43–52. doi:10.1006/taap.1995.1125

Boelsterli UA, Bedoucha M (2002) Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 63:1–10

Boess F, Bopst M, Althaus R et al (1998) Acetaminophen hepatotoxicity in tumor necrosis factor/lymphotoxin-alpha gene knockout mice. Hepatology 27:1021–1029. doi:10.1002/hep.20740

Bridges HR, Jones AJY, Pollak MN, Hirst J (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462:475–487. doi:10.1042/BJ20140620

Capron-Chivrac D, Reix N, Quenou C, Capron JP (1985) Acute hepatopathy caused by amiodarone. Study of a case and review of the literature. Gastroenterol Clin Biol 9:535–539

Carey MA, Van Pelt FNAM (2005) Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 216:41–48. doi:10.1016/j.tox.2005.07.015

Carvalho C, Correia S, Santos MS et al (2008) Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem 308:75–83. doi:10.1007/s11010-007-9614-3

Choi S (2003) Nefazodone (Serzone) withdrawn because of hepatotoxicity. Can Med Assoc J 169:1187

Christofferson DE, Yuan J (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22:263–268. doi:10.1016/jceb.2009.12.003

Coles B, Wilson I, Wardman P et al (1988) The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. Arch Biochem Biophys 264:253–260. doi:10.1016/0003-9861(88)90592-9

Cone CJ, Bachtyrycz AM, Murata GH (2010) Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother 44:1655–1659. doi:10.1345/aph.1P999

Cui L, Yoon S, Schinazi RF, Sonnadossi JP (1995) Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-ribofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 95:555–563. doi:10.1172/JCI117698

Daly AK, Donaldson PT, Bhatnagar P et al (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41:816–819. doi:10.1038/ng.379

Dawson S, Stahl S, Paul N et al (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130–138. doi:10.1124/dmd.111.040758

de Abajo FJ, Montero D, Madurga M, García Rodríguez LA (2004) Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 58:71–80. doi:10.1111/j.1365-2125.2004.02133.x

Degterev A, Huang Z, Boyce M et al (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1:112–119. doi:10.1038/nchembio711

den Braver-Sewradj SP, den Braver MW, Vermeulen NPE et al (2016) Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer. Toxicol In Vitro 33:71–79. doi:10.1016/j.tiv.2016.02.013

Desilets DJ, Shorr AF, Moraan KA, Holtzmuller KC (2001) Cholestasis jaundice associated with the use of metformin. Am J Gastroenterol 96:2257–2258. doi:10.1111/j.1365-2125.2004.02133.x

Dobson JL, Angus PW, Jones R et al (2005) Flucloxacillin-induced aplastic anaemia and liver failure. Transpl Int 18:487–489. doi:10.1111/j.1432-2277.2004.00014.x

Dunai ZA, Imre G, Barna G et al (2012) Staurosporine induces necrotic cell death under caspase-compromised conditions in U937 cells. PLoS One 7:e41945. doi:10.1371/journal.pone.0041945

Dykens JA, Jamieson JD, Marroquin LD et al (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103:335–345. doi:10.1093/toxsci/kpn024

Eriksson C, Gustavsson A, Kronvall T, Tysk C (2011) Hepatotoxicity of drug-induced liver injury in humans. Drug Metab Dispos 40:130–138. doi:10.1124/dmd.111.040758

Farrell GC (2002) Drugs and steatohepatitis. Semin Liver Dis 22:185–200. doi:10.1055/s-2002-30106
Fattinger K (2001) The endothelin antagonist bosentan inhibits the canicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231. doi:10.1067/mcp.2001.114667

Fissinger J-N, Huisman MV, Davidson BL et al (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293:681–689. doi:10.1001/jama.293.6.681

Fischer JJ, Michaelis S, Schrey AK et al (2010) Capture compound mass spectrometry sheds light on the molecular mechanisms of toxicity of two Parkinson drugs. Toxicol Sci 113:243–253. doi:10.1093/toxsci/kfp236

Fisher A, Croft-Baker J, Davis M et al (2002) Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 17:1362–1365. doi:10.1002/mds.10342

Floyd JS, Barbehenn E, Lurie P, Wolfe SM (2009) Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf 18:1238–1243. doi:10.1002/ps.1804

Fredriksson L, Herpers B, Benedetti G et al (2011) Diclofenac inhibits its tumour necrosis factor-a-induced nuclear factor-kB activation causing synergistic hepatocyte apoptosis. Hepatology 53:2027–2041. doi:10.1002/hep.24314

Fromenty B, Pessayre D (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67:101–154

Fromenty B, Fisch C, Berton A et al (1990a) Dual effect of amiodarone on mitochondrial respiration. Initial proinflammatory uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255:1377–1384

Fromenty B, Fisch C, Labbe G et al (1990b) Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 255:1371–1376

Funk C, Ponelle C, Scheuermann G, Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627–635

Galati G, Tafazoli S, Sabzevari O et al (2002) Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact 142:25–41

Gardner CR, Laskin JD, Dambach DM et al (2003) Exaggerated hepatotoxicity of acetaminophen in mice lacking tumor necrosis factor receptor-1. Potential role of inflammatory mediators. Toxicol Appl Pharmacol 192:119–130

Gómez-Lechón MJ, Ponsoda X, O’Connor E et al (2003) Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem Pharmacol 66:2155–2167

Guigui B, Perrot S, Berry JP et al (1988) Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 8:1063–1068

Gunawan BK, Liu Z-X, Han D et al (2006) c-Jun NH2-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131:165–178. doi:10.1053/j.gastro.2006.03.045

Haasio K, Sopanen L, Vaalavirta L et al (2001) Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J Neurol Transm 108:79–91. doi:10.1007/s007020170099

Haasio K, Koponen A, Penttilä KE, Nissinen E (2002a) Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur J Pharmacol 453:21–26

Haasio K, Nissinen E, Sopanen L, Heinonen EH (2002b) Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J Neural Transm 109:1391–1401. doi:10.1007/s00702-002-0748-x

Hadi M, Dragovic S, van Swelm R et al (2013) AMAP, the alleged non-toxic isomer of acetaminophen, is toxic in rat and human liver. Arch Toxicol 87:155–165. doi:10.1007/s00204-012-0924-1

Hagenbuch B, Meier PJ (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/H+ exchanger. J Clin Invest 93:1326–1331. doi:10.1172/JCI117091

Han W, Li L, Qiu S et al (2007) Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6:1641–1649. doi:10.1158/1535-7163.MCT-06-0511

Heath MF, Costa-Jussà FR, Jacobs JM, Jacobson W (1985) The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br J Exp Pathol 66:391–397

Henderson NC, Pollock KJ, Frew J et al (2007) Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut 56:982–990. doi:10.1136/gut.2006.104372

Hinson JA, Punford NR, Roberts DW (1995) Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab Rev 27:73–92. doi:10.1080/0360253950929816

Hu D, Wu C, Li Z et al (2015) Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: an in vitro model in mitochondria. Toxicol Appl Pharmacol 284:134–141. doi:10.1016/j.taap.2015.02.018

Ishida Y, Kondo T, Ohshima T et al (2002) A pivotal involvement of IFN-γ in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 16:1227–1236. doi:10.1096/fj.02-4046com

Jaeschke H (2015) Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig Dis 33:464–471. doi:10.1159/0003734090

Jaeschke H, Williams CD, Ramachandran A, Bajt ML (2012) Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 32:8–20. doi:10.1111/j.1478-3231.2011.02501.x

James LP, Mayeux PR, Hinson JA (2003a) Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499–1506. doi:10.1124/dmd.31.12.1499

James LP, McCullough SS, Lamps LW, Hinson JA (2003b) Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. Toxicol Sci 75:458–467. doi:10.1093/toxsci/kfg181

Kalugatar AS, Vaz ADN, Lame ME et al (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 33:243–253. doi:10.1124/dmd.104.001735

Keisu M, Andersson TB (2010) Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. doi:10.1007/978-3-642-00663-0_13

Kenne K, Skanberg I, Glinghammar B et al (2008) Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730–746. doi:10.1016/j.tiv.2007.11.014

Kenny JR, Maggs JL, Meng X et al (2004) Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. J Med Chem 47:2816–2825. doi:10.1021/jm030891w

Kindmark A, Juwaid A, Harbron CG et al (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8:186–195. doi:10.1038/sjpj.6500458
Kleiner DE, Gaffey MJ, Sallie R et al (1997) Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 10:192–199

Koek GH, Stricker BH, Blok AP et al (1994) Flucoxacinil-associated hepatic injury. Liver 14:225–229. doi:10.1111/j.1600-0676.1994.tb00799.x

Korlipara LVP, Cooper JM, Schapira AHV (2004) Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology 46:562–569. doi:10.1016/j.neuropharm.2003.10.015

Kostrubsky VE, Sinclair JF, Ramachandran V et al (2000) The role of mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353. doi:10.10111/j.1472-8206.2008.00608.x

Larson AM (2007) Acetaminophen hepatotoxicity. Clin Liver Dis 11:525–548. doi:10.1016/j.cld.2007.06.006

Larson AM, Polson J, Fontana RJ et al (2005) Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42:1364–1372. doi:10.1002/heap.20948

Latchoumycandane C, Seah QM, Tan RCH et al (2006) Leflunomide induced hepatic injury. Toxicol Sci 90:451–459. doi:10.1093/toxsci/kfj095

Kutoh E (2005) Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother 3:270–273. doi:10.1016/S1543-5946(05)00078-4

Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical studies. Fundam Clin Pharmacol 22:335–353. doi:10.1111/j.1472-8206.2008.00608.x

Lawson JA, Farhood A, Hopper RD et al (2000) The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol Sci 54:509–516

Lee WM, Larrey D, Olsson R et al (2005) Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:351–370

Lee EW, Lai Y, Zhang H, Unadkat JD (2006) Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. J Biol Chem 281:16700–16706. doi:10.1074/jbc.M513825200

Lees AJ, Ratziu V, Tolosa E, Oertel WH (2007) Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:944–948. doi:10.1136/jnnp.2006.097154

Leslie EM, Watkins PB, Kim RB, Brouwer KLR (2007) Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170–1178. doi:10.1124/jpet.106.119073

Lewis JH, Ranard RC, Caruso A et al (1989) Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 9:679–685. doi:10.1002/hep.1840090504

Lewis JH, Mullick F, Ishak KG et al (1990) Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 21:59–67. doi:10.1002/hum.1880210113

Li L, Jick H, Jick SS (2009) Updated study on risk of cholestatic liver disease and fialuracilin. Br J Clin Pharmacol 68:269–270. doi:10.1111/j.1365-2125.2009.03454.x

Lin Y, Choksi S, Shen H-M et al (2004) Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem 279:10822–10828. doi:10.1074/jbc.M313141200

Liu B, Tewari AK, Zhang L et al (2009) Proteomic analysis of protein tyrosine nitration after ischemia reperfusion injury: mitochondrial as the major target. Biochim Biophys Acta 1794:476–485. doi:10.1016/j.bbapap.2008.12.008

Lucena MI, Andrade RJ, Gomez-Outes A et al (1999) Case report: acute liver failure after treatment with nefazodone. Dig Dis Sci 44:2577–2579. doi:10.1023/A:1026620029470

Ma TKW, Yan BP, Lam Y-Y (2011) Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? a review of clinical data. Pharmacol Ther 129:185–194. doi:10.1016/j.pharmthera.2010.09.005

Madsen KG, Grönborg G, Skonberg C et al (2008a) Electrochemical oxidation of trilongatran: identification and characterization of the major reactive metabolite in liver microsomes. Chem Res Toxicol 21:2035–2041. doi:10.1021/tx8002214

Madsen KG, Skonberg C, Jurva U et al (2008b) Bioactivation of dicrofenac in vitro and in vivo: correlation to electrochemical studies. Chem Res Toxicol 21:1107–1119

Maeda K (2001) Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 135:299

Manno Y, Usui T, Kamiyama H (2007) Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28:13–18. doi:10.1002/bdd.527

Martignoni E, Cosentino M, Ferrari M et al (2005) Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 65:1820–1822. doi:10.1212/01.wnl.0000187066.81162.70

Masubuchi Y, Nakayama S, Horie T (2002) Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35:544–551. doi:10.1001/jhep.2002.31871

Masubuchi Y, Bourdi M, Reilly TP et al (2003) Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 304:207–212

Masubuchi Y, Suda C, Horie T (2005) Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 42:110–116. doi:10.1016/j.jhep.2004.09.015

May LD, Lefkowitz JC, Kram MT, Rubin DE (2002) Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 136:449–452

McGill MR, Jaeschke H (2013) Metabolism and disposition of acetaminophen: recent advances in relation to hepatitis and diagnosis. Pharm Res 30:2174–2187

McKenzie R, Fiedler MW, Sallie R et al (1995) Hepatic failure and lactacidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099–1105. doi:10.1056/NEJM199510263331702

Mofitt JS, Ale克斯unes LM, Kardas MJ et al (2007) Role of NAD(P)H quinone oxidoreductase 1 in clofibrate-mediated hepatotoxicity from acetaminophen. Toxicology 230:197–206. doi:10.1016/j.tox.2006.11.052

Monshi MM, Faulkner L, Gibson A et al (2013) Human leucocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for fialuracilin-induced liver injury. Hepatology 57:727–739. doi:10.1002/hep.26077

Moreau A, Téruel C, Beylot M et al (2009) A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Arch Toxicol (2016) 90:2979–3003
Morgan RE, van Staden CJ, Chen Y et al (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136:216–241. doi:10.1093/toxsci/ktt176

Nagasaka S, Abe T, Kawakami A, Kusaka I, Nakamura T, Ishikawa S, Saito TIS (2002) Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med 19:347–348

Nammour FE, Fayad NF, Peikin SR (2003) Metformin-induced cholestatic hepatitis. Endocr Pract 9:307–309. doi:10.4158/EP9.4.307

Neve EPA, Köfeler H, Hendriks DFG et al (2015) Expression and function of mARC: roles in lipogenesis and metabolic activation of ximelagatan. PLoS One 10:e0138487. doi:10.1371/journal.pone.0138487

Nissinen E, Kaheinen P, Penttilä KE et al (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. Eur J Pharmacol 340:287–294. doi:10.1016/S0044-8666(97)01431-3

Noé J, Stieger B, Meier PJ (2002) Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123:1659–1666

Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatan compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691–1698

Papantiratayflou M (2012) Cell death: programmed necrosis: putting the pieces together. Nat Rev Mol Cell Biol 13:135. doi:10.1038/nrm3292

Pichler WJ, Schindler L, Stäubli M et al (1988) Anti-amiodarone antibodies: detection and relationship to the development of side effects. Am J Med 85:197–202

Pinto AG, Cummings OWCN (2002) Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med 137:855–857

Pirovino M, Müller O, Zysset T, Honegger U (1988) Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology 8:591–598

Pollak PT (2010) How toxic is amiodarone to the liver? J Gastrointest Liver Dis 19:11–13

Powis G, See KL, Santone KS et al (1987) Quinoneimines as substrates for quinone reductase (NAD(P)H: quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity. Biochem Pharmacol 36:2473–2479. doi:10.1016/0006-2952(87)90519-3

Pumford NR, Halmes NC (1997) Protein targets of xenobiotic reactivators: detection and relationship to the development of acute hepatotoxicity. Arch Toxicol (2016) 90:2979–3003

Rätz Bravo AE, Drewe J, Schlenger RG et al (2005) Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med 33:128–134 (discussion 245–6)

Rigas B, Rosenfeld LE, Barwick KW et al (1986) Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann Intern Med 104:348–351

Rojo A, Fontán A, Mena MA et al (2001) Tolcapone increases plasma catecholamine levels in patients with Parkinson’s disease. Parkinsonism Relat Disord 7:93–96

Rusmann S, Kaye JA, Jick SS, Jick H (2005) Risk of cholestatic liver disease associated with fluvoxacin and fluvoxacin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 60:76–82. doi:10.1111/j.1365-2125.2005.02370.x

Saad T, Waterman M, Yassin H, Baruch Y (2013) Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. Int J Gen Med 6:703–706. doi:10.2147/IJGM.S49657

Salas VM, Corcoran GB (1997) Calcium-dependent DNA damage and adenosine 3',5'-cyclic monophosphate-independent glycogen phosphorylase activation in an in vitro model of acetaminophen-induced liver injury. Hepatology 25:1432–1438. doi:10.1002/hep.510250621

Salminen WF, Roberts SM, Pumford NR, Hinson JA (1998) Immunochemical comparison of 3'-hydroxycacetanilide and acetaminophen binding in mouse liver. Drug Metab Dispos 26:267–271

Scheen AJ (2001) Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 24:873–888

Schulman S, Wählender K, Lundström T et al (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatan. N Engl J Med 349:1713–1721. doi:10.1056/NEJMoa03104

Shah RR, Oates JS, Idle JR et al (1982) Impaired oxidation of debrisoquine in patients with peroxisome-neopathy. Br Med J (Clin Res Ed) 284:295–299

Shen S, Marchick MR, Davis MR et al (1999) Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxy-diclofenac. Chem Res Toxicol 12:214–222

Simpson KJ, Lukacs NW, McGregor AH et al (2000) Inhibition of tumour necrosis factor alpha does not prevent experimental paracetamol-induced hepatic necrosis. J Pathol 190:489–494. doi:10.1002/(SICI)1096-9896(200003)190:4<489:AID-PATH343>3.0.CO;2-V

Sirtori CR, Franceschini G, Galli-Kienle M et al (1978) Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 24:683–693

Sison-Young RLC, Mitsa D, Jenkins RE et al (2015) Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication. Toxicol Sci 147:412–424. doi:10.1093/toxsci/kfv136

Sison-Young RL, Lauschke VM, Johann E et al (2016) A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch Toxicol. doi:10.1007/s00204-016-1745-4

Smith KS, Smith PL, Heady TN et al (2003) In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 16:123–128. doi:10.1021/tr025569h

Srivastava A, Maggs JL, Antoine DJ et al (2010) Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol. doi:10.1007/978-3-642-00663-0_7

Stampfer BD, Mohar I, Kavanagh TJ, Nelson SD (2011) Proteomic analysis of acetaminophen-induced changes in mitochondrial protein expression using spectral counting. Chem Res Toxicol 24:549–558. doi:10.1021/tr1004198

Stewart DE (2002) Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 47:375–377
Stieger B, Fattinger K, Madon J et al (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422–430. doi:10.1016/S0016-5085(00)70224-1

Stravitz RT, Sanyal AJ (2003) Drug-induced steatohepatitis. Clin Liver Dis 7:435–451

Tang W (2003) The metabolism of diclofenac—enzymology and toxicology perspectives. Curr Drug Metab 4:319–329

Tang W, Stearns RA, Bandiera SM et al (1999) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 27:365–372

Terada H (1990) Uncouplers of oxidative phosphorylation. Environ Health Perspect 87:213–218

Tettey JN, Maggs JL, Rapeport WG et al (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 14:965–974

Tirmenstein MA, Hu CX, Gales TL et al (2002) Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 69:131–138

Tolman KG, Chandramouli J (2003) Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 7:369–379

Trials C, Manning FJ, Swartz M et al (1995) Review of the fialuridine (FIAU) clinical trials. In: Manning FJ, Swartz M (eds) Institute of Medicine (US) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials. National Academies Press (US), Washington (DC)

Uetrecht JP (2000) Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr Drug Metab 1:133–141

Vandenabeele P, Galluzzi L, Vanden Bergh T, Kroemer G (2010) Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11:700–714. doi:10.1038/nrm2970

Vredenburg G, Elias NS, Venkataraman H et al (2014) Human NAD(P)H:quione Oxidoreductase 1 (NQO1)-mediated inactivation of reactive quinonemine metabolites of diclofenac and mafenamic acid. Chem Res Toxicol 27:576–586. doi:10.1021/tx400431k

Vuppalanchi R, Liangpunsakul S, Chalasani N (2007) Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 102:558–562. doi:10.1111/j.1572-0241.2006.01019.x (quiz 693)

Wallentin L, Wilcox RG, Weaver WD et al (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789–797. doi:10.1016/S0140-6736(03)14287-0

Watkins PB (2005) Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 33:1–5. doi:10.1080/0192623059088306

Wright GI, Leeson GA, Zeiger AV, Lang JF (1973) Proceedings: the absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 49(Suppl 3):8–15

Wu Y, Geng X-C, Wang J-F et al (2016) The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. Cell Biol Toxicol 32:37–59. doi:10.1007/s10565-016-9316-2

Xu D, Nishimura T, Nishimura S et al (2014) Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med 11:e1001628. doi:10.1371/journal.pmed.1001628

Yagupsky P, Gazala E, Sofer S et al (1985) Fatal hepatic failure and encephalopathy associated with amiodarone therapy. J Pediatr 107:967–970

Yang K, Woodhead JL, Watkins PB et al (2014) Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 96:589–598. doi:10.1038/clpt.2014.158